However, as improved response to radiation and chemoradiation is directly linked to HPV-driven cancer biology in OPSCC patients [41], we recommend a combination of p16-IHC and HPV-DNA detection for clinical practice whenever considering to draw therapeutic consequences out of HPV-status. This evidence concerns the gene CDKN2A and cancer.